AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31542446 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Consumer Medication Information (C-CMI)
Number of subjects: 0
Study 31542446 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study 30241151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated in the United States/Canada (USC)
Number of subjects: 4736
Study 30241151 — intervention group
Group type: COMPARATOR
Intervention: Patients treated in Western Europe
Number of subjects: 4736
Study 30241151 — intervention group
Group type: COMPARATOR
Intervention: Patients treated in Latin America, Asia/Oceania/Africa, and Eastern Europe
Number of subjects: 4736
Study 30241151 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 4736
Study 27488457 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa anti-bullying program
Number of subjects: 2042
Study 27488457 — intervention group
Group type: COMPARATOR
Intervention: Control (usual school provision)
Number of subjects: 2042
Study 25694243 — intervention group
Group type: EXPERIMENTAL
Intervention: low-frequency tRNS (lf-tRNS)
Number of subjects: 154
Study 25694243 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency tRNS (hf-tRNS)
Number of subjects: 154
Study 25694243 — intervention group
Group type: EXPERIMENTAL
Intervention: whole frequency spectrum tRNS (wf-tRNS)
Number of subjects: 154
Study 23948349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense treatment (carboplatin AUC 6 mg/mL per min on day 1 and paclitaxel 80 mg/m2 on days 1, 8, and 15)
Number of subjects: 637
Study 23948349 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (carboplatin AUC 6 mg/mL per min and paclitaxel 180 mg/m2 on day 1)
Number of subjects: 637
Study 23948349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense treatment
Number of subjects: 637
Study 23948349 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 637
Study 20104529 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc
Number of subjects: 31
Study 20104529 — intervention group
Group type: COMPARATOR
Intervention: Control (azulene oral rinse)
Number of subjects: 31
Study 18386641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 50
Study 18386641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 16807754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyed test formulation administered intranasally
Number of subjects: 10
Study 16807754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral head position during administration
Number of subjects: 10
Study 14682142 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation (AHF) 1.3 Gy, twice a day, 5 weeks, total 57.2-70 Gy
Number of subjects: 303
Study 14682142 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation (AHF) 1.5 Gy, total 54-63 Gy
Number of subjects: 303
Study 14682142 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation (AHF) 1.7 Gy, total 56.1-57.83 Gy
Number of subjects: 303
Study 14682142 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (SF), total 58-70 Gy
Number of subjects: 303
Study 11007216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N hydrochloric acid perfusion
Number of subjects: 12
Study 11007216 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 12
Study 11007216 — intervention group
Group type: COMPARATOR
Intervention: Comparison of acid perfusion to saline perfusion
Number of subjects: 12
Study 8615463 — intervention group
Group type: EXPERIMENTAL
Intervention: knee-high, foam, single-pulse IPC device
Number of subjects: 26
Study 8615463 — intervention group
Group type: COMPARATOR
Intervention: thigh-high, vinyl, sequential-pulse IPC system
Number of subjects: 26
Study 1535419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin before myocardial infarction
Number of subjects: 2231
Study 1535419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin after myocardial infarction
Number of subjects: 2231
Study 1535419 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists after myocardial infarction
Number of subjects: 2231
Study 6727354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H‐labelled oestradiol
Number of subjects: 3
Study 6727354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H‐labelled oestriol
Number of subjects: 3
Study 6727354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H‐labelled oestradiol and oestriol
Number of subjects: 3
Study 30515552 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm A
Number of subjects: 45739
Study 30515552 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm B
Number of subjects: 45739
Study 30515552 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm C
Number of subjects: 45739
Study 27684533 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 455
Study 27684533 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib
Number of subjects: 455
Study 27684533 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of trastuzumab and lapatinib
Number of subjects: 455
Study 27684533 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly paclitaxel
Number of subjects: 455
Study 27684533 — intervention group
Group type: EXPERIMENTAL
Intervention: fluorouracil, epirubicin, and cyclophosphamide
Number of subjects: 455
Study 26293315 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS (Percutaneous tibial nerve stimulation)
Number of subjects: 227
Study 26293315 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 227
Study 23644651 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 16
Study 23644651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 16
Study 23644651 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 16
Study 20663996 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (250, 300, or 350 µg/kg as bolus before PCI, followed by 15, 20, or 25 µg/kg/min infusion)
Number of subjects: 140
Study 20663996 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (70-100 IU/kg bolus)
Number of subjects: 140
Study 19634959 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, manualized intervention (individual counseling and peer group education/support)
Number of subjects: 253
Study 19634959 — intervention group
Group type: COMPARATOR
Intervention: Control condition (resource referrals)
Number of subjects: 253
Study 16717320 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at special sedation points
Number of subjects: 9
Study 16717320 — intervention group
Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture at special sedation points
Number of subjects: 9
Study 16717320 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture of points for increasing 'Qi-energy'
Number of subjects: 9
Study 14766713 — intervention group
Group type: EXPERIMENTAL
Intervention: Double setup ETT
Number of subjects: 200
Study 14766713 — intervention group
Group type: COMPARATOR
Intervention: Single ETT
Number of subjects: 200
Study 11868762 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg tablets b.i.d. for 7 d
Number of subjects: 12
Study 11868762 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid 1000 mg tablets o.d. for 7 d
Number of subjects: 12
Study 12515162 — intervention group
Group type: EXPERIMENTAL
Intervention: L-HSA-Ara-AMP (35 mg/Kg daily for 5 days)
Number of subjects: 10
Study 7989928 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory regimen consisting of fractionated total-body irradiation (12 Gy total administered in 10 1.2-Gy fractions), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg).
Number of subjects: 96
Study 2543553 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet-fibre diet (mean 40 g FibrexR, 27 g dietary fibre per day)
Number of subjects: 12
Study 2543553 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study 2543553 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet-fibre diet
Number of subjects: 12
Study 2543553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study 1123455 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride (SERC), 20 mg
Number of subjects: 12
Study 1123455 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride (SERC), high dosage (16 mg)
Number of subjects: 12
Study 1123455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31349865 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified‐PIL
Number of subjects: 102
Study 31349865 — intervention group
Group type: EXPERIMENTAL
Intervention: No‐PIL
Number of subjects: 102
Study 31349865 — intervention group
Group type: COMPARATOR
Intervention: Standard‐PIL
Number of subjects: 102
Study 27714451 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI with gap balancing (PSI-GB)
Number of subjects: 50
Study 27714451 — intervention group
Group type: COMPARATOR
Intervention: PSI with conventional technique (PSI-S)
Number of subjects: 50
Study 26403410 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (methylprednisolone aceponat), applied once a day for three months (group A)
Number of subjects: 45
Study 26403410 — intervention group
Group type: COMPARATOR
Intervention: Topical calcineurin inhibitors (tacrolimus), applied twice a day for three months (group B)
Number of subjects: 45
Study 23948642 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on clinical variables (age, residence, body mass index, on-treatment heart rate and BP, prior myocardial infarction, heart failure, stroke/transient ischemic attack, smoking, diabetes, peripheral arterial disease, chronic kidney disease)
Number of subjects: 18484
Study 23948642 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 18484
Study 21480317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin therapy
Number of subjects: 871
Study 19472884 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protraction with rapid palatal expansion (RPE)
Number of subjects: 31
Study 19472884 — intervention group
Group type: COMPARATOR
Intervention: Maxillary protraction without rapid palatal expansion (RPE)
Number of subjects: 31
Study 16918513 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA-4 antagonist GW559090X (3 mg)
Number of subjects: 15
Study 16918513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) (500 microg)
Number of subjects: 15
Study 16918513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15307010 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg once-daily lamivudine (3TC)
Number of subjects: 554
Study 15307010 — intervention group
Group type: COMPARATOR
Intervention: 150 mg twice-daily lamivudine (3TC)
Number of subjects: 554
Study 15307010 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg twice-daily zidovudine
Number of subjects: 554
Study 15307010 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg once-daily efavirenz
Number of subjects: 554
Study 15307010 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events, disease progression, and HIV-associated conditions
Number of subjects: 554
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (triple-therapy: Clarithromycin, Amoxicillin, and Omeprazole for one week)
Number of subjects: 192
Study 11795863 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 192
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive patients (CagA positive)
Number of subjects: 192
Study 11795863 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 192
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 192
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA positive H. pylori infection
Number of subjects: 192
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 192
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA IgG detection
Number of subjects: 192
Study 11795863 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori DNA detection
Number of subjects: 192
Study 9463301 — intervention group
Group type: EXPERIMENTAL
Intervention: New allopurinol formulation (300 mg)
Number of subjects: 18
Study 9463301 — intervention group
Group type: COMPARATOR
Intervention: Reference allopurinol formulation
Number of subjects: 18
Study 8431665 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (0.1 mg/kg)
Number of subjects: 22
Study 8431665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3038987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (1% w/v)
Number of subjects: 10
Study 3038987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29461667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 100
Study 29461667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26850803 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil inhalation (5% for 10 min, three times a week for 4 weeks)
Number of subjects: 59
Study 26850803 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 59
Study 24225740 — intervention group
Group type: EXPERIMENTAL
Intervention: CYL concentrate supplementation group (CS group)
Number of subjects: 17
Study 24225740 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PL group)
Number of subjects: 17
Study 24225740 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant capsule group (AO group)
Number of subjects: 17
Study 23768271 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-4
Number of subjects: 10
Study 23768271 — intervention group
Group type: COMPARATOR
Intervention: Sham-CV4
Number of subjects: 10
Study 23768271 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 20634268 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation + exercise group
Number of subjects: 140
Study 20634268 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only group
Number of subjects: 140
Study 18709511 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554
Study 18709511 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (20-40 mg daily)
Number of subjects: 554
Study 16793163 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet (the 'back book') and usual physical therapy
Number of subjects: 142
Study 16793163 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy only with nonstandardized oral information
Number of subjects: 142
Study 16793163 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet (the 'back book')
Number of subjects: 142
Study 14738126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge containing 56.4mg (3 percent w/w) CPP-ACP
Number of subjects: 10
Study 14738126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge containing 18.8mg (1 percent w/w) CPP-ACP
Number of subjects: 10
Study 14738126 — intervention group
Group type: COMPARATOR
Intervention: Lozenge not containing CPP-ACP
Number of subjects: 10
Study 14738126 — intervention group
Group type: COMPARATOR
Intervention: No lozenge nil-treatment control
Number of subjects: 10
Study 10960928 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychoeducational group program for partners
Number of subjects: 36
Study 8636748 — intervention group
Group type: EXPERIMENTAL
Intervention: New York (NY) regimen
Number of subjects: 220
Study 8636748 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin-Frankfurt-Munster (BFM) regimen
Number of subjects: 220
Study 8636748 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 7 marrow evaluation
Number of subjects: 220
Study 8636748 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 14 marrow evaluation
Number of subjects: 220
Study 8636748 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 7 marrow with WBC count > 200,000/microL
Number of subjects: 220
Study 8636748 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 14 marrow evaluation for slow responders
Number of subjects: 220
Study 7936829 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxyacyl-CoA dehydrogenase measured with 3-ketopalmitoyl-CoA as substrate
Number of subjects: 8
Study 7936829 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme activities measured in fibroblasts
Number of subjects: 8
Study 2850904 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 10-20 mg/d
Number of subjects: 38
Study 2850904 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) 12.5-25 mg/d
Number of subjects: 38
Study 2850904 — intervention group
Group type: EXPERIMENTAL
Intervention: combination therapy (enalapril + HCTZ)
Number of subjects: 38
Study 2850904 — intervention group
Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 38
Study 2850904 — intervention group
Group type: COMPARATOR
Intervention: enalapril + HCTZ
Number of subjects: 38
Study 30475454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech Speech Generating Device (SGD)
Number of subjects: 35
Study 30475454 — intervention group
Group type: COMPARATOR
Intervention: Low-tech Picture Exchange Communication System (PECS)
Number of subjects: 35
Study 27661661 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs by intradiscal injection of 25 × 10 cells per segment under local anesthesia
Number of subjects: 24
Study 27661661 — intervention group
Group type: COMPARATOR
Intervention: Sham infiltration of paravertebral musculature with anesthetic
Number of subjects: 24
Study 26312580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Number of subjects: 71
Study 26312580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 26312580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU, 2000 IU, 4000 IU)
Number of subjects: 71
Study 26312580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 71
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 fractions of 3.8 Gy (n=60)
Number of subjects: 142
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 fractions of 7.2 Gy (n=82)
Number of subjects: 142
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response patients
Number of subjects: 142
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease patients
Number of subjects: 142
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: KPS ≤ 60 at start
Number of subjects: 142
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: KPS > 60 at start
Number of subjects: 142
Study 23289530 — intervention group
Group type: EXPERIMENTAL
Intervention: KPS improvement during therapy
Number of subjects: 142
Study 21893568 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials)
Number of subjects: 58
Study 21893568 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 58
Study 21893568 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 58
Study 18057912 — intervention group
Group type: EXPERIMENTAL
Intervention: Clo‐Met (100 mg clotrimazole and 100 mg metronidazole)
Number of subjects: 165
Study 18057912 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (100 mg)
Number of subjects: 165
Study 16931507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg/day
Number of subjects: 344
Study 16931507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.50 mg/day
Number of subjects: 344
Study 16931507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg/day
Number of subjects: 344
Study 16931507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 16931507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (all doses combined)
Number of subjects: 344
Study 16931507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 344
Study 12656937 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily left prefrontal rTMS (5 Hz, 110% motor threshold, 8 sec on, 22 sec off, over 20 min) for 2 weeks
Number of subjects: 23
Study 12656937 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily left prefrontal rTMS
Number of subjects: 23
Study 12656937 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 23
Study 11026517 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/day)
Number of subjects: 47
Study 11026517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soybean oil)
Number of subjects: 47
Study 7773117 — intervention group
Group type: EXPERIMENTAL
Intervention: Current MMT
Number of subjects: 0
Study 7773117 — intervention group
Group type: COMPARATOR
Intervention: Previous MMT and non-MMT
Number of subjects: 0
Study 7773117 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study 2110603 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 12
Study 2110603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 12
Study 2110603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 380367 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20-35 mg intravenously
Number of subjects: 20
Study 380367 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 30-40 mg intravenously
Number of subjects: 20
Study 29872922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically interesterified palm olein (IPO)
Number of subjects: 21
Study 29872922 — intervention group
Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 21
Study 29872922 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil (HOS)
Number of subjects: 21